A Phase I Multicenter, Open Label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MIL97 in Subjects With Advanced or Metastatic Solid Tumors
Latest Information Update: 18 Mar 2024
At a glance
- Drugs MIL 97 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Beijing Mabworks Biotech
- 11 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2026.
- 11 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.